Investor Presentation
Recent Acquisition
Avitide Inc. September 16, 2021
AVITIDE
Headquarters: Lebanon, NH
Founded: 2013
Co-Founders:
Kevin Isett, Ph.D. (CEO),
Warren Kett, Ph.D. (CSO),
Tillman Gerngross, Ph.D. (Chair)
Employees: 40
Manufacturing facilities: Lebanon, NH
ISO 9001:2005 certified
ā
Modular operations for volume flexibility
Business Model:
ā
Combination of custom ligand development
for select pharma partners and resin scale-up
Moving towards broader reach ligand/resin
programs
AAV (gene therapy), New modalities
>1E14
ligand library diversity
>40
unique ligand scaffolds
High diversity
improves the overall
probability of
success to identify
well-differentiated
binders
AVITIDE
AVITIDE
AVITIDE
This is a technology play with rapid
growth potential
$12.0
$10.0
$8.0
$6.0
$4.0
$2.0
$0.0
$2.5M
R REPLIGEN
INSPIRING ADVANCES IN BIOPROCESSING
FY 20
$4.5M (e)
FY 21 e
$10M (e)
FY 22 e
Avitide's revenue is
expected to double in 2022
and grow >50% in 2023View entire presentation